FDA has Xarelto concerns
July 2, 2013Sales and Marketing Bayer, Boehringer, FDA, Pradaxa, Xarelto
The FDA is unsure about an application to further extend the licence for Janssen and Bayer HealthCare’s blood thinner Xarelto …
Watermeadow shortlisted for medical education award
July 1, 2013Medical Communications Communique, Excellence in Ophthalmology, UK, Watermeadow Medical, award-winning agency, finalist, medical education, ophthalmology, programme
Watermeadow Medical is delighted that one of its educational programmes has been shortlisted for the ‘Excellence in Professional Education Programmes’ …
Watermeadow’s continued commitment to ethical publications
July 1, 2013Medical Communications CMPP, Medical Writer, Qualification, Watermeadow Medical, Writer, agency, editor, ethical, ethics, medical editor, medical writing, publication specialist, publications
As part of Watermeadow Medical’s commitment to ethical publications, five more of its editorial staff have qualified as Certified Medical …
Remicade copies set for European entry
July 1, 2013Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar
Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …
Aspen buys Merck facility and products in $1 billion deal
July 1, 2013Manufacturing and Production MSD, Merck, Oss, aspen
Africa’s largest drugmaker Aspen Pharmacare has agreed to buy a manufacturing facility owned by Merck & Co, plus a portfolio …
Ben Adams appointed editor of Pharmafocus
July 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ben Adams, McConaghie, Pharmafocus
Ben Adams has become the new editor of the monthly Pharmafocus newspaper and the Pharmafile.com website. Adams, formerly the senior …
Sanofi’s Lemtrada nears EU approval
July 1, 2013Sales and Marketing CHMP, Genzyme, Lemtrada, Sanofi
Sanofi’s multiple sclerosis drug Lemtrada has received a positive recommendation from the CHMP, meaning a European approval is likely just …
A call for harmony on clinical trials
July 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Frédéric Sgard, OECD, clinical trials
Clinical trials are an essential part of the development of medical treatments. They involve testing new medicines or new therapies, …
New chair for the BioIndustry Association
July 1, 2013The BioIndustry Association has appointed Dr Edward Hodgkin as its new chairman, effective from October this year.Hodgkin succeeds Tim Edwards, …
Lords: ‘Simplify pharma regulation’
July 1, 2013Sales and Marketing Lords, NICE, pharma, regulation
Investors are not putting their money into the UK’s regenerative medicine sector because of the high failure rate when it …
‘Three-person’ IVF consultation
June 28, 2013Research and Development, Sales and Marketing DoH, HFEA, IVF
The Department of Health is to publish draft guidelines later this year on a controversial IVF-based technique which would lead …
Survey: ‘Consultants prefer mailshots’
June 28, 2013Medical Communications, Sales and Marketing Onyx, digital, mailshots
Pharma should use standard marketing activities such as mailshots if they want to promote their products effectively in UK secondary …
Diabetes vaccine trial posts positive results
June 28, 2013Research and Development, Sales and Marketing TOL-3021, Vaccine, diabetes
A groundbreaking new study suggests that the body’s immune system can be taught to reverse the effects of type 1 …
Life appoints new account manager
June 28, 2013Medical Communications, Research and Development, Sales and Marketing Life, mead
Creative comms agency Life has expanded its client service team with the appointment of a new account manager.Kirsty Mead joins Life from Seven …
FDA issues final guidance on heparin testing
June 27, 2013Manufacturing and Production, Sales and Marketing FDA, heparin
Five years after the adulterated heparin scandal that claimed the lives of dozens of people in the US alone, the …
ImmTAC deal for Immunocore
June 27, 2013Research and Development, Sales and Marketing Genentech, ImmTAC, oxford biotech
Oxford-based biotech company Immunocore has signed what could be a $300 million deal with Genentech to discover and bring to …
Oxford BioTherapeutics hires chairman
June 27, 2013Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics, morton
Biotech firm Oxford BioTherapeutics has appointed Bryan Morton to be the company’s new non-executive chairman. Morton has over 30 years’ …
Contract research news in brief
June 27, 2013Research and Development PRA International, Parexel, Quanticate, TKL, WIL Research
A round-up of recent developments in the contract research sector, including KKR’s acquisition of PRA, a new Parexel business unit …
Astellas in $500m deal with Cytokinetics
June 27, 2013Sales and Marketing Astellas, cytokinetics
Astellas Pharma could pay out $40 million over the next two years to US firm Cytokinetics as part of a …
Heart failure treatment given Breakthrough Status
June 27, 2013Sales and Marketing Breakthrough Therapy Designation, Novartis, RLX03O, serelaxin
Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
